EMEA-000694-PIP03-17

Key facts

Invented name
Forxiga
Active substance
dapagliflozin
Therapeutic area
Cardiovascular diseases
Decision number
P/0202/2018
PIP number
EMEA-000694-PIP03-17
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Prevention of cardiovascular events in patients with chronic heart failure
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB

Tel. +44 (0)1625 230700
E-mail: paediatrics@astrazeneca.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating